2014 American Diabetes Association Scientific Sessions Highlights

ADA 2014 Scientific Sessions

Investigational Diabetes Therapy May Reduce HbA1c

Isis Pharmaceuticals announced results from its Phase 2 study of ISIS-GCGRRX in patients with type 2 diabetes uncontrolled on stable metformin therapy at the 2014 American Diabetes Association Scientific Sessions.

Results Announced for New Formulation of Hylenex

Halozyme Therapeutics announced results from CONSISTENT 1, a trial evaluating the use of Hylenex recombinant (hyaluronidase human injection) and a new formulation of Hylenex when used as pretreatment at the insulin infusion site in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion compared to no pre-treatment, at the 2014 American Diabetes Association Scientific Sessions.

Combo Once-Daily Insulin Therapy May be Efficacious in T2D

New Phase 3a results demonstrate that IDegLira, an investigational once-daily single injection combination of insulin degludec and liraglutide, for the treatment of patients with type 2 diabetes, maintained its glucose-lowering effect and confirmed safety evaluations for up to one year, as presented at the 2014 American Diabetes Association Scientific Sessions.